These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34629433)

  • 1. Chemotherapy and targeted therapies for meningiomas: what is the evidence?
    Graillon T; Tabouret E; Chinot O
    Curr Opin Neurol; 2021 Dec; 34(6):857-867. PubMed ID: 34629433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative treatments for meningiomas.
    Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; Régis J; Guedj E; Barlier A; Chinot O
    Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
    Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
    Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.
    Graillon T; Defilles C; Mohamed A; Lisbonis C; Germanetti AL; Chinot O; Figarella-Branger D; Roche PH; Adetchessi T; Fuentes S; Metellus P; Dufour H; Enjalbert A; Barlier A
    J Neurooncol; 2015 Aug; 124(1):33-43. PubMed ID: 26015296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of telomerase reverse transcriptase promoter gen mutations in high grade meningiomas.
    Cañas A; Jiménez E; Hakim F; Mejía JA; Ramón JF; Gómez D; Jaramillo-Velásquez D; Bermúdez S; Useche N; Pineda D; Cifuentes H; Becerra A; Muñoz Á; Santoyo N; Ruíz-Patiño A; Sotelo C; Archila P; Rodríguez J; Ávila J; Ordoñez-Reyes C; García-Robledo JE; Ricaurte L; Rojas L; Feo O; Burgos R; Ramírez C; Arrieta O; Zatarain-Barrón L; Vargas C; Carranza H; Otero J; Cardona AF
    Biomedica; 2022 Dec; 42(4):574-590. PubMed ID: 36511679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib.
    Cardona AF; Ruiz-Patiño A; Zatarain-Barrón ZL; Hakim F; Jiménez E; Mejía JA; Ramón JF; Useche N; Bermúdez S; Pineda D; Cifuentes H; Rojas L; Ricaurte L; Pino LE; Balaña C; Arrieta O
    PLoS One; 2019; 14(6):e0217340. PubMed ID: 31220093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort.
    Le Van T; Graillon T; Jacob J; Vauleon E; Feuvret L; Boch AL; Boetto J; Boone M; Bronnimann C; Caire F; De Barros A; Delaitre M; Di Stefano AL; Dore M; Ducray F; Dufour C; Engelhardt J; Fontaine D; Froelich S; Helleringer M; Huchet A; Joncour A; Jouanneau E; Mallereau CH; Monfilliette A; Le Fur E; Zemmoura I; Chinot O; Sanson M; Kalamarides M; Loiseau H; Peyre M
    J Neurooncol; 2021 May; 153(1):55-64. PubMed ID: 33778930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic
    Brastianos PK; Twohy EL; Gerstner ER; Kaufmann TJ; Iafrate AJ; Lennerz J; Jeyapalan S; Piccioni DE; Monga V; Fadul CE; Schiff D; Taylor JW; Chowdhary SA; Bettegowda C; Ansstas G; De La Fuente M; Anderson MD; Shonka N; Damek D; Carrillo J; Kunschner-Ronan LJ; Chaudhary R; Jaeckle KA; Senecal FM; Kaley T; Morrison T; Thomas AA; Welch MR; Iwamoto F; Cachia D; Cohen AL; Vora S; Knopp M; Dunn IF; Kumthekar P; Sarkaria J; Geyer S; Carrero XW; Martinez-Lage M; Cahill DP; Brown PD; Giannini C; Santagata S; Barker FG; Galanis E
    J Clin Oncol; 2023 Jan; 41(3):618-628. PubMed ID: 36288512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant meningioma mTOR mutated and precision medicine.
    Villani V; Tanzilli A; Vidiri A; Giangaspero F; Ciliberto G; Olivi A; Pace A
    Neurol Sci; 2023 Mar; 44(3):1073-1075. PubMed ID: 36567410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma.
    Chamberlain MC
    Curr Opin Oncol; 2012 Nov; 24(6):666-71. PubMed ID: 22759739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Landscape of genetic variants in sporadic meningiomas captured with clinical genomics.
    Leclair NK; Shen E; Wu Q; Wolansky L; Becker K; Li L; Bulsara KR
    Acta Neurochir (Wien); 2022 Sep; 164(9):2491-2503. PubMed ID: 35881312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular biological determinations of meningioma progression and recurrence.
    Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
    PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review.
    Graillon T; Romano D; Defilles C; Saveanu A; Mohamed A; Figarella-Branger D; Roche PH; Fuentes S; Chinot O; Dufour H; Barlier A
    J Neurosurg; 2017 Sep; 127(3):660-669. PubMed ID: 27982767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
    Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
    Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical treatment of recurrent meningiomas.
    Chamberlain MC; Barnholtz-Sloan JS
    Expert Rev Neurother; 2011 Oct; 11(10):1425-32. PubMed ID: 21955199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
    Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
    Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.
    Karsy M; Guan J; Cohen A; Colman H; Jensen RL
    Neurosurg Clin N Am; 2016 Apr; 27(2):249-60. PubMed ID: 27012389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.